In a mouse model of MM, the administration of an activin antagonist—a soluble form of the extracellular domain of the type IIA receptor of activin coupled to the Fc fragment of Ig (RAP-011)—decreased the number of osteolytic lesions, increased bone mass, and decreased tumor burden [360]. Here, INHBE is linked to Miyoshi myopathy.